Organogenesis (ORGO) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Organogenesis is set to release its Q2 2025 earnings report, with expectations of an earnings per share (EPS) of ($0.01) and revenue of $104.75 million.
• The company has seen a decrease in stock price, trading down by 2.3%, with a recent stock price of $4.66 and a market capitalization of $591.12 million.
• Insider activity included the purchase of 142,379 shares by Lori Freedman, increasing her holdings by 20.48% and reflecting confidence in the company's future.

Organogenesis (NASDAQ:ORGO - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results after the market closes on Thursday, August 7th. Analysts expect Organogenesis to post earnings of ($0.01) per share and revenue of $104.75 million for the quarter. Organogenesis has set its FY 2025 guidance at EPS.

Organogenesis (NASDAQ:ORGO - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.17). Organogenesis had a negative return on equity of 4.00% and a negative net margin of 3.46%. The business had revenue of $86.69 million for the quarter, compared to analyst estimates of $90.77 million. On average, analysts expect Organogenesis to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Organogenesis Stock Up 1.7%

ORGO traded up $0.08 during trading on Monday, hitting $4.59. 226,959 shares of the company's stock were exchanged, compared to its average volume of 1,499,126. The business's 50 day moving average is $3.81 and its two-hundred day moving average is $4.03. Organogenesis has a fifty-two week low of $2.28 and a fifty-two week high of $6.71. The stock has a market cap of $581.63 million, a P/E ratio of -26.91 and a beta of 1.76.

Insider Transactions at Organogenesis

In related news, insider Lori Freedman acquired 9,022 shares of the firm's stock in a transaction that occurred on Friday, June 6th. The stock was acquired at an average price of $2.99 per share, for a total transaction of $26,975.78. Following the completion of the acquisition, the insider owned 846,459 shares of the company's stock, valued at approximately $2,530,912.41. This represents a 1.08% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have bought a total of 252,264 shares of company stock worth $725,732 in the last three months. Company insiders own 33.00% of the company's stock.

Hedge Funds Weigh In On Organogenesis

An institutional investor recently bought a new position in Organogenesis stock. Strs Ohio purchased a new position in Organogenesis (NASDAQ:ORGO - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 24,400 shares of the company's stock, valued at approximately $105,000. 49.57% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ORGO has been the topic of several research reports. Cantor Fitzgerald restated an "overweight" rating and set a $7.00 price objective on shares of Organogenesis in a report on Tuesday, July 15th. BTIG Research reiterated a "buy" rating on shares of Organogenesis in a report on Tuesday, July 15th.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.